Home >
News >
Product News >
Endoret® (PRGF®) rewrites the way of treating patients >

Endoret® (PRGF®) rewrites the way of treating patients

Wednesday, November 27, 2019

Endoret® (PRGF®) is a 100 % endogenous technology, based on platelet-enriched plasma obtained from patient’s own blood. The high regenerative potential and versatility make Endoret® (PRGF®) a MUST for a wide range of clinical applications.

Endoret® (PRGF®) is a 100 % endogenous technology, based on platelet-enriched plasma obtained from patient’s own blood.

The high regenerative potential and versatility make Endoret® (PRGF®) a MUST for a wide range of clinical applications.

Highly effective hard and soft tissue regeneration technology which:

  • Accelerates healing
  • Shortens treatment times
  • Reduces postoperative complications and re-treatments costs
  • Improves patient’s experience

Why is Endoret® (PRGF®) effective?

  • Its platelet concentration has been optimized to trigger the regenerative processes and maximize the biological response
  • It provides a strong and elastic 3D fibrin scaffold, enriched with Growth Factors (NO red and white cells), whose time of release can be controlled
  • It is leucocyte FREE, which reduces inflammation and increases the stability of the fibrin scaffold

How did we learn about its effectiveness?

There is important scientific evidence (around 150 in vitro, in vivo, clinical trials) that prove it.